Spero Therapeutics, Inc. (FRA:2HA)

Market Cap	110.15M
Revenue (ttm)	34.56M
Net Income (ttm)	-37.36M
Shares Out	n/a
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550
Average Volume	28
Open	1.814
Previous Close	1.830
Day's Range	1.810 - 1.978
52-Week Range	0.455 - 2.655
Beta	n/a
RSI	45.74
Earnings Date	Mar 13, 2026

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous my...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2HA

Financial Performance

Financial numbers in USD